ZIBRIO Secures $100

ZIBRIO has secured $100,000 in new funding from investors, marking a significant milestone for the company dedicated to fall prevention.

ZIBRIO is commercializing advanced space technology to address the critical issue of falls, which are the leading cause of trauma death globally.

This public health challenge results in an estimated $50 billion in medical costs annually, a figure projected to double within the next decade.

The company's flagship product, the ZIBRIO Stability scale, offers a quick and easy method to measure weight, balance, and fall risk through a simple standing test.

This precision measurement provides a balance score that can predict an individual's likelihood of falling within the next 12 months and offers a risk trajectory spanning over 30 years.

The accompanying software delivers personalized physician recommendations designed to help patients improve their stability.

Clinical observations have shown that ZIBRIO technology can lead to a 74% reduction in falls, translating into substantial cost-savings and enabling real-time adjustments to interventions.

This recent capital infusion underscores investor confidence in ZIBRIO's innovative approach to health technology and its potential to revolutionize fall risk management.

The $100,000 in funding will enable ZIBRIO to accelerate its growth initiatives, further develop its proprietary technology, and expand its market presence.

The company aims to bring its impactful solution to a broader audience, empowering individuals and healthcare providers to proactively manage fall risk.

Looking ahead, ZIBRIO plans to leverage this investment to scale its operations and continue its mission of changing the game in fall prevention.

By providing immediate insights into balance and risk, ZIBRIO is poised to make a significant impact on public health and reduce the economic burden associated with falls.